Delivery bottleneck for RASAGILIN ABZ 1 MG: This is why the drug is currently not available

As the Federal Institute for Drugs and Medical Devices (BfArM) announced on November 14, 2023, there are currently delivery bottlenecks for the drug RASAGILIN ABZ 1 MG. You can find out why there are currently restrictions and what the medicine is used for here on news.de!

Many pharmacists and pharmacists are currently busy finding alternatives for missing medicines, because the preparations are now also in short supply in Germany. More and more patients therefore have to pay attention to important things Medication Avoid it or switch to alternative treatments. RASAGILIN ABZ 1 MG is also currently affected.

Causes of delivery problems with RASAGILIN ABZ 1 MG

The notification of the supply shortage for the drug sold by AbZ-Pharma GmbH (D), will remain in effect for the period from September 4th, 2023 to March 18th, 2024. It is currently unknown whether the drug has any particular relevance for hospitals. The Federal Institute did not propose an alternative preparation for RASAGILIN ABZ 1 MG. It could still be advantageous in the Pharmacy to ask for alternatives. In any case, one thing to note is that it is absolutely not advisable to look for alternatives abroad.

Delivery bottlenecks can arise again and again for various reasons, such as production problems and regulatory hurdles that can affect the release and transport of medicines. According to the BfArM, production problems are responsible for the current shortage of RASAGILIN ABZ 1 MG, with “problems in manufacturing” being cited as a detail.

RASAGILIN ABZ 1 MG: The details about the medication

Rasagiline AbZ 1 mg is a prescription medicine and is particularly important because of its active ingredient, rasagiline mesilate.
For example, the medicine is prescribed for the following diagnoses:

  • Primary Parkinson’s syndrome, unspecified: Without fluctuation in effect

The following can be summarized about the medication and its application:

  • The medicine contains the active ingredient rasagiline and is used in adults to treat Parkinson’s disease. It can be used either with or without levodopa (another medicine used to treat Parkinson’s disease).
  • Parkinson’s disease involves a loss of cells that produce dopamine in the brain. Dopamine is a chemical found in the brain that is involved in the regulation of controlled movements. The preparation helps to both increase and maintain dopamine levels in the brain.

Delivery problems and causes at a glance

drugRASAGILIN ABZ 1 MG
ManufacturerAbZ-Pharma GmbH – business address –
PZN11058043
active ingredientRasagiline mesilate
Validity periodSeptember 4th, 2023 to March 18th, 2024
relevant in the hospitalno
Alternative preparationnot specified
Reason for the delivery bottleneckProblems in manufacturing

When will the medication be available again?

There is a possibility of an extension of the period of validity in the case of RASAGILIN ABZ 1 MG due to the ongoing bottleneck.

Pharmacies are currently facing a particular challenge and must respond to the bottlenecks with smart decisions. For some medications it is possible to deviate from the prescribed pack size or to provide alternatives. Although this seems to be working well at the moment, this temporary solution should not become a lasting solution to the problems.
There have been efforts to curb supply bottlenecks for medicines for a long time. There are now laws and strategy papers at both national and European levels. Both immediate measures and long-term strategies were recorded. It now remains to be seen how the implementation of the new regulations will affect the problem.

+++ Editorial note: Our reports on delivery bottlenecks are produced by our editors and regularly enriched with new research. The associated current data in the article is entered by us from the Federal Institute for Drugs and Medical Devices (BfArM), which is done automatically in order to be able to provide the most up-to-date information possible (last on November 14th, 2023). If you have any comments or questions, please contact [email protected]. +++

Read everything about the topic of medication shortages here and here on news.de.

follow News.de already at Facebook, Twitter, Pinterest and YouTube? Here you will find hot news, current videos and a direct line to the editorial team.

roj/news.de/BfArM

roj/news.de


source site